~36 months in last 5 years
reflecting commitment to bring medicines to patients as quickly and safely as possible
A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used whenever possible to strengthen the evidence base for as many of our programs as possible.
* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
‡ In addition to the above programs, AMJEVITA™/AMGEVITA™, MVASI™, and KANJINTI™ have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA™ has been approved by the FDA.